From: Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil
 |  | 6 months | 12 months | 24 months |
---|---|---|---|---|
Overall | Â | N (%) | N (%) | N (%) |
 | For patients with HIV VL | 754/980 (76.9) | 802/1054 (76.1) | 637/938 (67.9) |
 | Best-case scenarioa | 1085/1311 (82.8) | 1059/1311 (80.8) | 1010/1311 (77.0) |
 | Worst-case scenariob | 754/1311 (57.5) | 802/1311 (61.2) | 637/1311 (48.6) |
Stratified by type of ART regimen | Â | Â | Â | |
NNRTI-based | Â | Â | Â | Â |
 | For patients with HIV VL | 583/740 (78.8) | 603/784 (76.9) | 503/711 (70.7) |
 | Best-case scenario | 830/987 (84.1) | 806/987 (81.7) | 779/987 (78.9) |
 | Worst-case scenario | 583/987 (59.1) | 603/987 (61.1) | 503/987 (51.0) |
PI-based | Â | Â | Â | |
 | For patients with HIV VL | 171/240 (71.3) | 199/270 (73.7) | 134/227 (59.0) |
 | Best-case scenario | 255/324 (78.7) | 253/324 (78.1) | 231/324 (71.3) |
 | Worst-case scenario | 171/324 (52.8) | 199/324 (61.4) | 134/324 (41.4) |
Stratified by calendar year of ART initiation | Â | Â | Â | |
2000-2004 | Â | Â | Â | Â |
 | For patients with HIV VL | 157/252 (62.3) | 188/297 (63.3) | 171/287 (59.6) |
 | Best-case scenario | 297/392 (75.8) | 283/392 (72.2) | 276/392 (70.4) |
 | Worst-case scenario | 157/392 (40.1) | 188/392 (48.0) | 171/392 (43.6) |
2005-2010 | Â | Â | Â | Â |
 | For patients with HIV VL | 597/728 (82.0) | 614/757 (81.1) | 466/651 (71.6) |
 | Best-case scenario | 788/919 (85.7) | 776/919 (84.4) | 734/919 (79.9) |
 | Worst-case scenario | 597/919 (65.0) | 614/919 (66.8) | 466/919 (50.7) |